← Leaderboards
Chad J Roy
Tulane University Of Louisiana
$2,554,223
Attributed
$2,926,868
Total exposure
28
Grants
27
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $745.3K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,926,868 · 28
By mechanism
P51$1,339,348 · 25
R56$745,291 · 1
U19$600,160 · 1
U54$242,069 · 1
Top collaborators
- Seth H. Pincus1 shared
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Bobby J Gormus$240,638
- Pete J Didier$2,580,809
- Elizabeth Schmidt Didier$8,050,961
- Laura S Levy$4,511,732
- Marlene S Orandle$1,359,068
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantResourcesUnited States National Institutes Of HealthFundingAerosolsSourceAnimalsNonhuman PrimateResearch PersonnelPrimatesVaccinesBaseComputer Retrieval Of Information On Scientific Projects DatabaseInstitutionBiologicalDoseExposure ToResponseInfectionAntibodiesDisease ModelIn VivoSafetySyndrome
Grant awards (29)
Non-human-primate core for translational vaccine research$600,160
U19 · FY2025 · AI · contact PI
Core Services: Division of Microbiology, Infectious Disease Aerobiology Core$65,584
P51 · FY2019 · OD · contact PI
Core Services: Division of Microbiology, Infectious Disease Aerobiology Core$65,584
P51 · FY2018 · OD · contact PI
In Vivo Mechanisms of Antibody-mediated Protection from Aerosolized Ricin Toxin$745,291
R56 · FY2017 · AI
CONTINUED DEVELOPMENT OF RIVAX VACCINE FOR RICIN$37,186
P51 · FY2011 · RR · contact PI
NONHUMAN PRIMATE MODEL OF MELIODOSIS$37,186
P51 · FY2011 · RR · contact PI
HUMAN ANTIBODIES FOR THERAPEUTIC INTERVENTION OF SEB EXPOSURE$37,186
P51 · FY2011 · RR · contact PI
INFECTIOUS DISEASE AEROBIOLOGY CORE$37,186
P51 · FY2011 · RR · contact PI
POSTEXPOSURE PROPHYLAXIS AND TREATMENT OF AEROSOLIZED SMALLPOX$37,186
P51 · FY2011 · RR · contact PI
VACCINE DEVELOPMENT FOR ALPHAVIRUSES$37,186
P51 · FY2011 · RR · contact PI
MONOCLONAL ANTIBODY SEB IMMUNOPROTECTANT$61,801
P51 · FY2010 · RR · contact PI
NONHUMAN PRIMATE MODEL OF MELIODOSIS$61,801
P51 · FY2010 · RR · contact PI
A NONHUMAN PRIMATE MODEL OF RICKETTSIA PROWAZEKII INFECTION (EPIDEMIC TYPHUS)$61,801
P51 · FY2010 · RR · contact PI
HUMAN ANTIBODIES FOR THERAPEUTIC INTERVENTION OF SEB EXPOSURE$61,801
P51 · FY2010 · RR · contact PI
CONTINUED DEVELOPMENT OF RIVAX VACCINE FOR RICIN$61,801
P51 · FY2010 · RR · contact PI
VACCINE DEVELOPMENT FOR ALPHAVIRUSES$61,801
P51 · FY2010 · RR · contact PI
POSTEXPOSURE PROPHYLAXIS AND TREATMENT OF AEROSOLIZED SMALLPOX$61,801
P51 · FY2010 · RR · contact PI
INFECTIOUS DISEASE AEROBIOLOGY CORE$61,801
P51 · FY2010 · RR · contact PI
MELIODOSIS$57,967
P51 · FY2009 · RR · contact PI
VACCINE DEVELOPMENT FOR ALPHAVIRUSES$57,967
P51 · FY2009 · RR · contact PI
CONTINUED DEVELOPMENT OF RIVAX VACCINE FOR RICIN$57,967
P51 · FY2009 · RR · contact PI
MONOCLONAL ANTIBODY SEB IMMUNOPROTECTANT$57,967
P51 · FY2009 · RR · contact PI
HUMAN ANTIBODIES FOR THERAPEUTIC INTERVENTION OF SEB EXPOSURE$57,967
P51 · FY2009 · RR · contact PI
A NONHUMAN PRIMATE MODEL OF RICKETTSIA PROWAZEKII INFECTION (EPIDEMIC TYPHUS)$57,967
P51 · FY2009 · RR · contact PI
EFFICACY OF FLAGELLIN/F1/V MUCOSAL PLAGUE VACCINE IN C MACAQUES AND C AETHIOPS$57,967
P51 · FY2009 · RR · contact PI
A nonhuman primate model of Rickettsia prowazekii infection$242,069
U54 · FY2008 · AI · contact PI
NONHUMAN PRIMATE MODEL OF MELIODOSIS$24,103
P51 · FY2008 · RR · contact PI
EFFICACY OF FLAGELLIN/F1/V MUCOSAL PLAGUE VACCINE IN CYNOMOLGUS AND CHLOROCEBUS$30,392
P51 · FY2007 · RR · contact PI
A NONHUMAN PRIMATE MODEL OF RICKETTSIA PROWAZEKII INFECTION (EPIDEMIC TYPHUS)$30,392
P51 · FY2007 · RR · contact PI